Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 8/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 8/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 8/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 8/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 8/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18321978 | 0.89 | BRD4 (0.38) | BRD4CYP26A1NAAACYP24A1DRD3 | |
| SCHEMBL20952649 | 0.87 | CYP26A1 (0.37) | BRD4CYP26A1GRIN2BGRIN2DGRIN3B | |
| SCHEMBL20241193 | 0.85 | BRD4 (0.35) | BRD4CYP26A1CYP24A1MTNR1A | |
| SCHEMBL18322028 | 0.81 | BRD4 (0.38) | BRD4CYP26A1MTNR1A | |
| SCHEMBL20952680 | 0.76 | BRD4 (0.34) | BRD4CYP26A1NAAACYP24A1DRD3 | |
| SCHEMBL18325712 | 0.74 | CA1 (0.36) | GRIN2B | |
| SCHEMBL18322555 | 0.73 | DHODH (0.36) | GRIN2B | |
| SCHEMBL28620218 | 0.73 | CYP26A1 (0.43) | BRD4CYP26A1CYP24A1DRD3DRD2 | |
| SCHEMBL20952602 | 0.71 | NQO1 (0.37) | BRD4GRIN2BGRIN2DGRIN3BGRIN1 | |
| SCHEMBL18322098 | 0.71 | NAAA (0.36) | NAAAMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3766878-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| CN-108137557-B | Nrf2 modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3766878-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3307729-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-09-02 | — | — | EP | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20180169110-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| WO-2018104766-A1 | 3-(2,3-DIHYDRO-1H-INDEN-5-YL)PROPANOIC ACID DERIVATIVES AND THEIR USE AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-14 | — | — | WO | disclosed |
| EP-3307729-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016203401-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272095-B2 | NRF2 regulators | NFE2L2, KEAP1, NQO1 | BRD4 727/4885CYP26A1 1198/4885GRIN2B 3210/4885 |
| US-20190224212-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | BRD4 727/4885CYP26A1 1198/4885GRIN2B 3210/4885 |
| US-20180169110-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | BRD4 727/4885CYP26A1 1198/4885GRIN2B 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.